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ABSTRACT
Glioblastoma (GBM) is the most common malignant brain tumor in adults, with
a median survival of 15 months. These poor clinical outcomes have prompted the
development of drugs that block neoplastic cancer cell growth; however, non-neoplastic
cell-derived signals (chemokines and cytokines) in the tumor microenvironment may
also represent viable treatment targets. One such chemokine, Ccl5, produced by lowgrade tumor-associated microglia, is responsible for maintaining neurofibromatosis
type 1 (NF1) mouse optic glioma growth in vivo. Since malignant gliomas may achieve
partial independence from growth regulatory factors produced by non-neoplastic
cells in the tumor microenvironment by producing the same cytokines secreted
by the stromal cells in their low-grade counterparts, we tested the hypothesis
that CCL5/CCL5-receptor signaling in glioblastoma creates an autocrine circuit
important for high-grade glioma growth. Herein, we demonstrate that increased CCL5
expression was restricted to both human and mouse mesenchymal GBM (M-GBM), a
molecular subtype characterized by NF1 loss. We further show that the NF1 protein,
neurofibromin, negatively regulates Ccl5 expression through suppression of AKT/
mTOR signaling. Consistent with its role as a glioblastoma growth regulator, Ccl5
knockdown in M-GBM cells reduces M-GBM cell survival in vitro, and increases mouse
glioblastoma survival in vivo. Finally, we demonstrate that Ccl5 operates through an
unconventional CCL5 receptor, CD44, to inhibit M-GBM apoptosis. Collectively, these
findings reveal an NF1-dependent CCL5-mediated pathway that regulates M-GBM
cell survival, and support the concept that paracrine factors important for low-grade
glioma growth can be usurped by high-grade tumors to create autocrine regulatory
circuits that maintain malignant glioma survival.

INTRODUCTION

therapies have resulted in only modest increases in overall
survival, highlighting the urgent need to identify more
effective therapies for these brain malignancies.
Over the past decades, numerous reports
have described an instructive role for the tumor
microenvironment in glioma formation and maintenance
[4]. In this regard, glioblastomas contain a rich nonneoplastic component, including endothelial cells and
immune system cells (e.g., microglia and macrophages),
whose function is dictated by small molecules responsible
for their recruitment and activation. One class of these
proteins, chemokines, is critical for microglia and
macrophage infiltration and activation through the

Malignant gliomas (glioblastoma or GBM) are the
most common brain tumor in adults, with approximately
over 13,000 individuals in the United States dying
from their cancer each year. After initial diagnosis, the
median survival is only 9 months [1, 2], which improves
to ~15 months following surgical resection, radiation
and chemotherapy [3]. In an effort to improve clinical
outcomes for people with this deadly cancer, numerous
conventional and biologically-based anti-neoplastic
treatments have been evaluated that specifically target the
rapidly dividing cancer cells. Unfortunately, these newer
www.impactjournals.com/oncotarget
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expression of chemokine receptors on their plasma
membranes. Consistent with an ecosystem paradigm in
which non-neoplastic cells attracted by cancer cells in turn
support neoplastic cell growth, inhibition of chemokine
expression or chemokine receptor function has been shown
to attenuate both low-grade and high-grade glioma growth
in numerous experimental preclinical model systems
in vivo. For example, CCL2 recruits regulatory T cells and
myeloid-derived suppressor cells to increase GBM growth
[5], as well as indirectly increases glioma invasiveness
by stimulating IL-6 secretion from tumor-associated
microglia (TAM) [6]. In addition, CXCL12 and its
receptors CXCR4/CXCR7 function by maintaining GBM
stem-like cell survival and increasing glioma cell invasion
[7, 8]. Similarly, colony stimulating factor-1 (CSF-1)
creates a supportive glioma microenvironment, such that
silencing CSF-1-receptor signaling on macrophages is
sufficient to reduce high-grade glioma growth in mice
[9, 10]. Together, these experimental observations establish
a fundamental role for chemokines in glioma biology.
In addition to the chemokines mentioned above, we
have recently discovered that Ccl5 produced by tumorassociated microglia is a potent paracrine regulator of
neurofibromatosis type 1 (NF1)-associated murine lowgrade optic glioma growth [11]. In this experimental
system, Ccl5 was sufficient to stimulate Nf1-deficient
optic nerve glial cell proliferation in vitro, whereas
Ccl5 antibody-mediated inhibition attenuated mouse
optic glioma proliferation in vivo. Interestingly, CCL5
has recently emerged as a key member of an autocrine
cytokine circuit critical for KRAS-driven lung cancer
growth [12]. Since the NF1 protein, neurofibromin,
functions as a negative regulator of RAS, specifically
K-RAS in astroglial cells [13, 14], and NF1 mutation/
loss characterizes the mesenchymal GBM (M-GBM)
molecular subtype [15], we sought to determine whether
Ccl5 expression creates a unique autocrine circuit for
mesenchymal glioblastoma growth.
In this report, we describe for the first time, that
increased CCL5 expression is enriched in both human and
mouse M-GBM with NF1 loss. Leveraging Nf1-deficient
murine M-GBM models, we further demonstrate that Ccl5
shRNA-mediated knockdown increases glioblastoma cell
apoptosis in vitro, as well as extends mouse glioblastoma
survival in vivo. Moreover, neurofibromin negatively
regulates Ccl5 expression through RAS/AKT/mTOR
pathway activation. Lastly, Ccl5 produced by the M-GBM
cells acts in a cell autonomous fashion to increase
M-GBM cell survival using a non-conventional CCL5
receptor, CD44, to suppress programmed cell death.
Collectively, these findings broaden the concept that
growth regulatory factors produced by non-neoplastic
cells in the low-grade glioma microenvironment are
employed to establish autocrine circuits in high-grade
gliomas, thus facilitating a state of relative stromal
independence.
www.impactjournals.com/oncotarget

Ccl5 functions in a cell-autonomous fashion to
increase M-GBM survival
Based on our previous studies examining CCL5
expression and function in low-grade glioma, we first
sought to determine whether CCL5 expression was higher
in human GBM tumors relative to non-neoplastic brain.
Using the GSE16011 [16] dataset, for which normal brain
was available for comparison, CCL5 mRNA levels were
higher in GBM samples relative to their non-neoplastic
counterpart (Figure 1A). We next analyzed CCL5 mRNA
expression in the four GBM molecular subtypes using data
from the Cancer Genome Atlas (TCGA, provisional), and
found that mesenchymal GBM (M-GBM) exhibited the
highest levels of CCL5 mRNA expression, while proneural
GBM (PN-GBM) expressed the lowest (Figure 1B).
This relative enrichment of CCL5 expression in
the mesenchymal subtype, which frequently exhibits
loss of function mutations in the NF1 tumor suppressor
gene [15], prompted us to focus on murine models
characterized by Nf1 loss. Using two representative mouse
M-GBM cell lines (1861 and 4622), which lack Nf1 and
Tp53 expression [17], and two representative mouse
proneural GBM cell lines ((2)61 and (5)54), which retain
neurofibromin expression (Figure 1C) [18], we found that
Ccl5 levels were elevated in the culture medium of mouse
M-GBM cells relative to PN-GBM cells, as well as to
wild-type primary mouse astrocytes (Figure 1D).
To determine whether M-GBM cell growth was
dependent on Ccl5 expression, 1861 (M-GBM) cells were
grown in the presence of mouse Ccl5 (mCcl5). mCcl5
treatment increased cell growth, as revealed by ~14%
increase in BrdU incorporation relative to the vehicle
treatment (Figure 2A). Next, we reduced Ccl5 levels in
1861 cells by shRNA-mediated knockdown (KD). Using
two independent constructs (shCcl5-1 and shCcl5-2), Ccl5
protein levels were reduced to ~20% of control levels (LacZ
shRNA; Figure 2B), resulting in reduction in cell number
(Figure 2C) and cell growth (BrdU incorporation; Figure 2D)
as a consequence of increased apoptosis (increased
cleaved caspase-3 expression and %TUNEL+ cells;
Figure 2E–2G). Similar results were obtained using another
M-GBM cell line (4622; Supplementary Figure 1A–1E).
Importantly, treating PN-GBM cells with mCcl5 did not
affect cell growth, suggesting that Ccl5 is not a regulator for
PN-GBM growth (Supplementary Figure 1F).
Based on these in vitro results, we also sought to
determine whether Ccl5 is required for M-GBM growth
in vivo. Control (shLacZ) and Ccl5 KD (shCcl5-1 and
shCcl5-2) 1861 cells were stereotactically implanted
into the striata of 4-week-old wild-type C57BL/6 mice.
Both Ccl5 KD groups demonstrated reduced Ccl5 levels
(Figure 3A), reduced cell proliferation (%Ki67+ cells,
Figure 3B, 3C) at time of death, as well as longer survival
32978
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Neurofibromin negatively regulates Ccl5
expression through suppression of AKT/mTOR
pathway activation

relative to the control (shLacZ) group (Figure 3D). In
addition, tumor implants dissected at 6-weeks postimplantation demonstrated reduced Ccl5 levels, increased
apoptosis (cleaved caspase-3 expression), and reduced cell
proliferation (PCNA expression) in the Ccl5 KD groups
(Supplementary Figure 2).
Given the role of Ccl5 as a chemokine, it may
recruit monocytes to the implantation site to facilitate
tumor growth; however, we found no change in the
number of recruited monocytes or chemokine expression
within the tumor between the control and Ccl5 KD groups
(data not shown). In addition, we sought to determine
whether Ccl5 produced by non-neoplastic cells contributes
to M-GBM tumor growth by comparing M-GBM cell
growth in wild-type versus Ccl5−/− mouse striata. Mouse
survival and tumor proliferation were similar between
the two groups, arguing against a major stromal source
for Ccl5 in mediating the observed M-GBM survival
effects (Supplementary Figure 3). Collectively, these
observations demonstrate that Ccl5 positively regulates
M-GBM growth in vivo and in vitro through an autocrine
stimulatory mechanism.

Since increased CCL5 expression predominates in
the M-GBM molecular subtype and mouse Nf1-deficient
GBM cells exhibit reduced growth following Ccl5 KD, we
tested the hypothesis that the NF1 protein (neurofibromin)
function is responsible for regulating Ccl5 expression.
Using primary brainstem astrocytes from postnatal
day 1 mice (Nf1flox/flox astrocytes infected with Ad5-LacZ
virus, Nf1+/+; Nf1flox/flox astrocytes infected with Ad5Cre virus, Nf1−/−) (Supplementary Figure 4A), Ccl5
levels in the medium were increased in Nf1−/− astrocytes
relative to wild-type (Nf1+/+) controls (Figure 4A).
To establish causality, we re-introduced the functional
domain of neurofibromin (NF1-RAS GTPase-activating
protein regulatory domain [NF1-GRD; GRD-WT];
Supplementary Figure 4B). A mutant NF1-GRD construct
(NF1-GRDR1276P; GRD-Mut) defective at suppressing RAS
activity was used as a control for RAS-GAP activity [19].
Expression of WT, but not mutant, NF1-GRD reduced

Figure 1: M-GBM express high levels of CCL5. (A) Human GBM samples (GSE16011 [16]) have elevated CCL5 mRNA levels

relative to normal brain (NB). **p = 0.0023. (B) CCL5 mRNA expression (Log2 Z-score) in TCGA GBM (provisional) samples segregated by
molecular subgroup reveals that mesenchymal and proneural GBM express the highest and lowest CCL5 levels, respectively. **p = 0.0095;
****p < 0.0001. n = 106, 55, 102, and 96 for the mesenchymal, neural, classical and proneural molecular GBM subgroups, respectively. (C)
M-GBM cells are neurofibromin deficient, while PN-GBM cells express neurofibromin. (D) Ccl5 ELISA analysis of the culture medium
reveals higher levels of Ccl5 in M-GBM cells relative to PN-GBM cells and primary astrocytes. ****p < 0.0001. FC, fold change.
www.impactjournals.com/oncotarget
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Ccl5 levels in 1861 cells (Figure 4B), demonstrating that
neurofibromin negatively regulates Ccl5 expression.
Neurofibromin regulates glioma cell growth
through the AKT/mTOR pathway [20, 21], such that
Nf1−/− astrocytes exhibit AKT/mTOR hyperactivation
relative to Nf1+/+ (wild-type) astrocytes (Supplementary
Figure 4A). Consistent with this neurofibromin regulatory
function, AKT/mTOR activity in 1861 cells was reduced
following NF1-GRD expression (Supplementary
Figure 4C). Moreover, AKT pharmacological inhibition
(MK2206) of M-GBM cells similarly reduced AKT
activity (Figure 4C, 4D) and Ccl5 expression (Figure 4E).
In addition, AKT inhibition in 1861 cells reduced mTOR
activity (Figure 4F, 4G), and mTOR inhibition using
rapamycin (Figure 4F, 4G) reduced Ccl5 expression
(Figure 4H). The concentrations and durations of inhibitor
treatments were specifically selected so that cell growth was
not affected (Supplementary Figure 4D), arguing that any
potential changes in Ccl5 expression were a secondary effect
of suppressed cell growth. As a complementary approach,
we employed shRNA knockdown of Raptor, a molecule
critical for the function of mTOR complex-1 (Figure 4I).
Similar to rapamycin treatment, Raptor KD reduced Ccl5
expression (Figure 4J). However, in these experiments, cell
growth was inhibited following Raptor KD (Supplementary
Figure 4E), requiring that the amount of Ccl5 present in the
medium be normalized to the total cell number.
Since MEK/ERK activation is also elevated
following NF1 loss [22], we analyzed Ccl5 expression

following PD-0325901 (PD901, MEK inhibitor) treatment.
In these experiments, MEK inhibition did not change Ccl5
expression (Supplementary Figure 5). Collectively, these
experiments establish RAS-GAP/AKT/mTOR signaling
as the primary mechanism underlying neurofibromin
regulation of Ccl5 expression.

Ccl5 controls M-GBM survival through CD44
CCL5 functions by binding to G-protein coupled
receptors, including CCR (C-C chemokine receptor) 1,
3 and 5. Surprisingly, Ccr1, Ccr3 or Ccr5 mRNA levels
were nearly undetectable in M-GBM cells (Supplementary
Figure 6), prompting us to investigate non-conventional
CCL5 receptors (GPR75, CXCR4 and CD44) as potential
binding partners [23, 24]. In these experiments, only Cd44
mRNA was detected in 1861 and 4622 cells (Figure 5A),
which also observed at the protein level (Figure 5B).
Importantly, CD44 mRNA expression in human GBM
subtypes was highest in the mesenchymal group, and was
lowest in the proneural group (Figure 5C).
To determine whether CD44 was necessary for
M-GBM cell survival, we reduced Cd44 expression in
1861 cells using shRNA. Following Cd44 KD, there
was increased apoptosis (cleaved caspase-3 expression
and %TUNEL+ cells) relative to controls (LacZ KD)
(Figure 5D, 5E). In order to demonstrate that CD44
functions as the receptor for Ccl5 in 1861 cells, Cd44
KD cells were treated with mCcl5. Following Cd44

Figure 2: Ccl5 functions in a cell-autonomous fashion to increase M-GBM cell survival. (A) Increased BrdU incorporation

was observed in 1861 cells following treatment with mouse Ccl5 (mCcl5). Vehicle was 0.5% BSA in PBS. **p = 0.009. (B) ELISA analysis
of 1861 cell medium shows that Ccl5 KD (shCcl5-1, shCcl5-2) cells produce less Ccl5 compared to control (shLacZ) cells. ****p < 0.0001.
FC, fold change. (C) Ccl5 KD cells exhibit reduced cell numbers. *p = 0.0428 (shLacZ vs shCcl5-1), and p = 0.0162 (shLacZ vs shCcl5-2).
(D) Ccl5 KD cells exhibit reduced cell growth (BrdU incorporation). ****p < 0.0001. (E) Western blotting demonstrates increased cleaved
caspase-3 (c-caspase-3) expression following Ccl5 KD. (F, G) Ccl5 KD increases the percentage of TUNEL+ cells (green; arrows). DAPIstained nuclei (inset) are shown in blue. **p = 0.0039 (shLacZ vs shCcl5-1), and p = 0.0063 (shLacZ vs shCcl5-2). Scale bar, 25 μm.
www.impactjournals.com/oncotarget
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KD, mCcl5 could no longer increase 1861 cell growth
(Figure 6A). Similarly, Ccl5 KD in Cd44 KD cells
(Figure 6B) did not change cell growth (Figure 6C),
establishing that the growth-promoting effects of Ccl5
require CD44 expression on M-GBM cells. In order to
test whether other CD44 ligands function in a similar
fashion as Ccl5, we reduced Cd44 using shRNA in
Ccl5 KD cells (shCcl5 + shCd44), and compared cell
proliferation to that observed in Ccl5 KD (shCcl5) and
control (shLacZ) cells. It should be noted that the shLacZ
and shCcl5 cells were further infected with virus carrying

the shLacZ construct as an internal control for a second
round of viral infection. We observed no further reduction
of cell proliferation in Ccl5 KD cells following Cd44
knockdown (Figure 6D–6F), suggesting that this prosurvival pathway is specific to the interaction between
Ccl5 and CD44, and is not regulated by other CD44
ligands. Taken together, these data support a model in
which Nf1 loss in M-GBM cells leads to hyperactivation
of the AKT/mTOR pathway, which positively regulates
Ccl5 expression and increases M-GBM cell survival
through CD44 signaling (Figure 6G).

Figure 3: Ccl5 knockdown reduces M-GBM growth and prolongs mouse survival in vivo. Ccl5 KD (shCcl5-1, shCcl5-2) and

control (shLacZ) 1861 cells were implanted into the striata of C57BL/6 mice. Ccl5 KD groups have fewer Ccl5+ (red; A), Ki67+ cells (B, C,
arrow) relative to controls. *p = 0.0145; **p = 0.0014. Scale bars, 10 μm (A) and 50 μm (B). (D) Kaplan-Meier survival curves demonstrate that
the Ccl5 KD groups have prolonged survival relative to controls. Each group contains 9–10 mice. *p = 0.0117; **p = 0.0037 (Log-rank test).
www.impactjournals.com/oncotarget
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counterparts achieve partial stromal independence by
producing the very growth factors elaborated by nonneoplastic cells in low-grade gliomas. In this study, we
demonstrate that M-GBM cells express high levels of
CCL5 that provides an auto-stimulatory signal to increase
cell survival. Similarly, in other studies, M-GBM cells
express high levels of CXCL12, which forms another
autoregulatory loop with its receptor CXCR4/CXCR7,
to increase GBM cell proliferation [8, 29, 30]. In NF1associated low-grade gliomas, CXCL12 also serves as a
paracrine factor that drives the growth of neoplastic Nf1−/−
astrocytes [33]. These findings support the idea that highgrade glioma cells achieve certain degrees of stromal
independence by producing growth factors previously
provided by non-neoplastic stromal cells in the low-grade
glioma tumor microenvironment.
CCL5 is a potent chemokine operative in several types
of cancers, including lymphoma, melanoma, prostate cancer
and breast cancer [34]. However, while CCL5 function in
glioma has not been fully elucidated, several reports have
suggested that it might be an important chemokine in this
setting. First, one of the main CCL5 receptors, CCR5, is
expressed in U87 and U251 glioblastoma cell lines, such
that its knockdown inhibits U87 growth in nude mice [35].
Second, CCL5 mRNA and protein expression are elevated
in both tumor tissue and serum from patients with highgrade glioma [36]. Lastly, CCL5 is produced by microglia

Chemokines were originally described as key
signaling molecules in cancer biology by virtue of
their ability to recruit stromal cells (e.g., macrophages,
endothelial cells) to the developing tumor [25, 26].
While this is one important function for these immune
modulatory proteins, emerging evidence suggests that
chemokines and cytokines may create autocrine growth
regulatory circuits that facilitate tumor expansion. In this
regard, CXCR2 signaling has been shown to regulate
KRAS-induced pancreatic cancer growth [27], whereas
IL-8 serves as an autocrine growth factor for malignant
mesothelioma maintenance [28]. In the context of
glioma, CXCL12/CXCL12-receptor (CXCR4/CXCR7)
autoregulatory signaling has been demonstrated to be
important for glioblastoma survival [8, 29, 30] and
angiogenesis [31], while CX3CL1/CX3CR1 axis signaling
in glioma cells controls glioma cell invasion [32].
The emergence of such autoregulatory chemokine/
chemokine receptor loops relevant to glioma growth
prompted us to examine a recently-identified paracrine
signal (CCL5), produced by low-grade glioma-associated
microglia [11], as a potential autocrine signaling molecule
in high-grade glioma. While low-grade gliomas are
dependent on growth-facilitatory signals from the tumor
microenvironment, we hypothesize that their malignant

Figure 4: Ccl5 expression in M-GBM cells is regulated by neurofibromin-mediated AKT/mTOR pathway suppression.

(A) ELISA analysis demonstrates greater Ccl5 levels in the medium from Nf1−/− astrocytes relative to their wild-type (Nf1+/+) counterparts.
*p = 0.01. FC, fold change. (B) Wild-type NF1-GRD (GRD-WT) expression in 1861 cells reduced Ccl5 expression relative to the NF1-GRD
R1276P mutant (GRD-Mut). ****p < 0.0001. (C, D) Treatment of 1861 cells with MK2206 (AKT inhibitor) reduced AKT activity
(phospho-AKTS473/AKT ratio) compared to DMSO (vehicle control). **p = 0.0012. (E) ELISA reveals reduced Ccl5 expression following
MK2206 treatment. *p = 0.0258. FC, fold change. (F, G) MK2206 or rapamycin (mTOR inhibitor) treatment reduced mTOR activity
(phospho-S6S240/S244/S6 ratio). *p = 0.0362 (DMSO vs MK2206) and p = 0.0116 (DMSO vs rapamycin). (H) Rapamycin-treated 1861 cells
had reduced Ccl5 levels in the medium compared to DMSO controls. *p = 0.0313. FC, fold change. (I) Western blotting demonstrates that
shRNA-mediated Raptor KD (shRaptor-1 and shRaptor-2) reduced Raptor protein expression in 1861 cells relative to control (shLacZ)
vector. (J) Raptor KD results in reduced Ccl5 levels in the medium. **p = 0.002 (shLacZ vs shRaptor-1), and p = 0.0034 (shLacZ vs
shRaptor-2). FC, fold change.
www.impactjournals.com/oncotarget
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in the microenvironment of murine Nf1 optic glioma, and
is increased in low-grade gliomas (pilocytic astrocytoma)
relative to non-neoplastic tissue [11]. In this latter study,
CCL5 treatment increased optic nerve glial proliferation
in vitro, whereas antibody-mediated CCL5 inhibition
reduced optic glioma growth in vivo.
CCL5 typically functions by binding to its receptors
CCR1, CCR3 and/or CCR5. Surprisingly these receptors
were not detectable in M-GBM cells. Instead, M-GBM
cells express the non-conventional CCL5 receptor, CD44,
and use this receptor to maintain tumor cell survival.
CD44 is a cell surface glycoprotein that can function
as a co-receptor for extracellular matrix components,
growth factors and chemokines. CD44 plays several
critical roles in GBM and drives GBM cell invasion,
proliferation and drug resistance. CD44 expression is
increased in GBM compared to low-grade gliomas and
high levels of CD44 are associated with worse survival
of GBM patients [37]. Inhibiting CD44 function using
monoclonal antibodies or RNA silencing reduced GBM
growth in vivo and prolonged mouse survival [38, 39]. The
interaction between CD44 and its ligands (e.g., hyaluronic
acid and osteopontin) modulates multiple aspects of
glioma biology. Activation of CD44 by hyaluronic acid

was shown to increase glioma cell invasion [40–43]. In
addition, osteopontin-CD44 interaction induces cleavage
of the intracellular domain of CD44, increases a stem
cell phenotype, and increases the growth of PN-GBM
cells [44]. In this study, we found that the interaction
between Ccl5 and CD44 enhances cell survival in
M-GBM cells. This pro-survival effect is specific to Ccl5,
and does not appear to involve other CD44 ligands, since
Cd44 knockdown in Ccl5 KD cells does not further reduce
cell growth. Our study expands our understanding of the
potential mechanisms by which CD44 regulates GBM
maintenance.
CCL5 employs CD44 as an alternative receptor
to facilitate the entry of HIV virus [24], where it forms
a complex with CD44 and Src kinases to activate ERK
signaling. In our studies, ERK activity in M-GBM
cells was not reduced following Ccl5 KD (data not
shown), suggesting that a distinct signaling pathway is
activated following Ccl5 binding to CD44 in M-GBM
cells. Previous studies have demonstrated increased cell
survival following CD44 activation in several different
cancers. For example, CD44 protects chronic lymphocytic
leukemia cells from spontaneous and induced cell death
by increasing expression of the MCL-1 pro-survival

Figure 5: CD44 is required for M-GBM cell survival. (A) qPCR analysis of Cd44 mRNA in spleen (positive control), primary

astrocytes, mesenchymal GBM (M-GBM) and proneural GBM (PN-GBM) cells reveals higher Cd44 mRNA levels in M-GBM cells relative
to PN-GBM cells and primary astrocytes. ****p < 0.0001. FC, fold change. (B) CD44 protein is detected by Western blot in M-GBM, but
not in PN-GBM, cells. (C) CD44 mRNA expression (Log2 Z-score) in TCGA GBM (provisional) samples segregated by molecular subgroup
reveals that mesenchymal and proneural GBM express the highest and lowest CD44 levels, respectively. ****p < 0.0001. (D) Cd44 KD 1861
cells (shCd44) have increased cleaved caspase-3 (c-caspase-3) expression relative to control (shLacZ) cells. (E) Increased %TUNEL+ cells
(inset) are observed following Cd44 KD (green; arrows). DAPI-stained nuclei are shown in blue. *p = 0.0288. Scale bar, 25 μm.
www.impactjournals.com/oncotarget
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Figure 6: Ccl5 regulates M-GBM survival through CD44. (A) Cd44 KD 1861 cells treated with vehicle (0.5% BSA in PBS) or

mouse Ccl5 (mCcl5) show no difference in BrdU incorporation. n.s., not significant. (B) ELISA analysis shows that shCd44 + shCcl5 cells
have reduced levels of secreted Ccl5 relative to controls (shCd44 + shLacZ). ****p < 0.0001. FC, fold change. (C) Ccl5 KD in Cd44 KD
cells did not change BrdU incorporation. n.s., not significant. (D) ELISA analysis shows that Ccl5 KD cells (shCcl5 + shLacZ and shCcl5 +
shCd44) have reduced levels of secreted Ccl5 relative to control cells (shLacZ + shLacZ). ****p < 0.0001. ***p = 0.0002. FC, fold change.
n.d., not detected. (E) Western blotting demonstrates that Cd44 KD cells (shCcl5 + shCd44) have less CD44 protein relative to other cells
(shLacZ + shLacZ and shCcl5 + shLacZ). (F) Cd44 KD in Ccl5 KD cells did not change BrdU incorporation. n.s., not significant. (G)
Proposed model for Ccl5 regulation of M-GBM cell survival.
www.impactjournals.com/oncotarget
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protein [45], while CD44 activation in breast cancer
cells induces c-Jun mediated survival [46]. It has been
suggested in GBM that CD44 also inhibits the Hippomediated apoptotic signaling pathway to achieve resistance
to reactive oxygen species- or cytotoxic agent-induced
stress [39]. Further work will be required to determine how
CD44 regulates cell survival in M-GBM cells.
GBM tumors are genetically heterogeneous and
can be divided into mesenchymal, classical, neural and
proneural subtypes. Herein, we focused on studying the
behavior of mesenchymal GBM since Ccl5 has the highest
expression in this group. One common feature of the
M-GBM subtype is NF1 loss/mutation, which results in
impaired neurofibromin RAS suppression. Consistent
with this observation, we demonstrated that neurofibromin
directly regulates CCL5 expression through RAS signaling.
First, we show that ectopic expression of a functional,
but not mutant, NF1-GAP-related domain reduced Ccl5
expression. Second, Nf1 loss in primary astrocytes resulted
in increased Ccl5 expression. Third, pharmacological
inhibition of RAS downstream effector activation (AKT/
mTOR) suppressed Ccl5 expression in M-GBM cells.
Collectively, these results elucidate one mechanism by
which Ccl5 expression is controlled by RAS.
The Ccl5-mediated autocrine circuit identified in this
study may not apply to other GBM subtypes, given that
they do not express high levels of either CCL5 or CD44.
In fact, we have shown that treating murine PN-GBM cells
with Ccl5 did not increase cell growth. While multiple
signaling pathways contribute to GBM tumorigenesis, we
report one in which a chemokine-driven autocrine pathway
supports GBM cell survival. The regulation of chemokines
by oncogenic signaling pathways suggests that other
brain cancer-associated mutations might similarly
modulate chemokine production. Further dissection of the
chemokine/cytokine networks regulated by these tumor
suppressor/oncogenic pathways might uncover unique
immune modulatory programs with differential impact
not only on tumor cell growth, but also on the stromal cell
types in the tumor microenvironment.
Lastly, while Ccl5 silencing results in ~20%
reduction in cell growth in vitro, there was a ~70%
reduction in tumor cell growth following Ccl5 KD
in vivo. The greater cell survival benefit in vivo raises
the possibility that CCL5 may not solely function in
an autocrine manner, but may also recruit monocytes
(macrophages/microglia) to the tumor and enhance tumor
growth in a paracrine manner. However, we found no
difference in the percent of intratumoral Iba1+ monocytes
in mice bearing Ccl5 KD versus control (LacZ KD)
M-GBM cells (data not shown). Since it is possible that
attenuated Ccl5 expression alters the functional status of
tumor-associated macrophages/microglia, current studies
are focused on identifying potential changes in the tumor
microenvironment conferred by reduced glioblastoma
tumor cell Ccl5 production in vivo.
www.impactjournals.com/oncotarget

In summary, we demonstrate, for the first time,
that CCL5 functions in an autocrine growth-promoting
circuit, and establish a new receptor responsible for CCL5
function in mesenchymal glioblastoma cells. We further
show that key oncogenic signaling pathways, like RAS,
operate to modulate chemokine expression. As such, these
studies expand the role of chemokines in dictating glioma
biology, and suggest that paracrine growth regulatory
signals produced by non-neoplastic cells in the low-grade
glioma microenvironment may be converted to autocrine
tumor maintenance circuits in high-grade malignancies
relevant to mesenchymal glioblastoma survival in vitro
and in vivo.

MATERIALS AND METHODS
Human CCL5 and CD44 expression analysis
Expression values for CD44 and CCL5 (Glioblastoma,
TCGA Provisional, mRNA Expression z-Scores) were
obtained from the MSKCC computational biology cancer
genomics portal (http://www.cbioportal.org), which contains
annotated TCGA data [47, 48]. Tumor subtype classification
was performed as previously described [15].

Mice
4-week-old male C57BL/6 mice were purchased
from Taconic, and used in accordance with an approved
Animal Studies Committee protocol at Washington
University.

Cell culture
Mouse mesenchymal glioblastoma cells (1861 and
4622) were maintained as previously described [49], while
mouse proneural glioblastoma cells ((2)61 and (5)54)) were
derived from PDGFB-driven tumor-bearing mice [18] and
grown in mouse neural stem cell medium (STEMCELL
Technologies, 05700 and 05701), supplemented with
20 ng/ml hEGF (Sigma-Aldrich, E9644), 10 ng/ml
hFGF (R&D systems, 233-FB-025) and 2 μg/ml heparin
(STEMCELL Technologies, 07980). Wild-type and
Nf1−/− primary astrocytes were generated and maintained
as previously described [14, 50, 51]. Before performing
qPCR, ELISA or Western blotting, all cells were cultured
under the same condition for at least 24 hours.

Lentiviral infection
pLKO.1 plasmids with shRNAs targeting LacZ,
Ccl5 (shCcl5-1 and shCcl5-2), and Cd44 were obtained
from the Genome Institute at Washington University, while
shRaptor-1 and shRaptor-2 plasmids were purchased
(Addgene, 21339 and 21340) (Supplementary Table 1).
shRNAs were prepared and cells infected as previously
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Intracranial injections

reported [49]. MSCV-NF1-GRD-WT and mutant control
constructs [19] were transfected into 1861 cells using
X-tremeGENE 9 DNA transfection reagents (Roche
Life Science, XTG9-RO) according the manufacturer’s
protocol.

5 × 104 1861 cells were implanted into the striatum
of 4-week-old C57BL/6 mice as previously described
[49]. Mice were monitored daily, and euthanized when
moribund. Kaplan-Meier survival curves were generated,
and differences between control (shLacZ) and Ccl5 KD
(shCcl5-1 and shCcl5-2) groups analyzed using the Logrank test. For mCcl5 ELISA and Western blotting of the
implant, tissue around the tumor implantation site was
dissected 6-weeks post-implantation, followed by lysing
the tissue as described previously [14, 52].

Pharmacologic treatments
1861 cells were treated with 0.4 μM ZSTK474
(Selleckchem, S1072), 1 μM MK2206 (Selleckchem,
S1078), 5 nM rapamycin (Selleckchem, S1039), 1 nM PD0325901 (PD901; Selleckchem, S1036) or DSMO (vehicle
control, Sigma-Aldrich, D8418) for 4 hours at 37°C.

Immunohistochemistry

BrdU incorporation

Implanted mouse brains were fixed at the time
of death or deemed moribund by the veterinary staff,
embedded in paraffin and processed as described previously
[53], followed by performing immunohistochemistry using
primary and secondary antibodies (Supplementary Table 2).
Ccl5 signal was amplified using tyramide signal
amplification as described previously [11].

Cells were plated in 96-well plates, and treated with
250 ng/mL mCcl5 (R&D systems, 478-MR-025) or 0.5 %
BSA in PBS (vehicle control) for 4 hours at 37°C. BrdU was
added to the cell culture 2 hours before fixing the cells and
performing the BrdU ELISA assay (Roche Life Science,
11647229001) according the manufacturer’s protocol.

Statistical analyses

Terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL)

Data analysis was performed using Prism GraphPad.
Unpaired two-tailed Student’s t tests were used to
determine the difference between two groups. All data
were presented as mean values with standard error of
mean (SEM). All in vitro experiments were repeated at
least three times with similar results.

Cells maintained in 0.5% fetal bovine serum for
24 hours were fixed with 4% PFA, and TUNEL+ cells
detected using the fluorescence-based in situ cell death
detection kit (Roche Life Science, 11684795910). The
number of TUNEL+ cells was normalized to the total cell
number (DAPI+ nuclei) using NIH ImageJ software.
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